Posted: June 25, 2009

NaturalNano Begins Feasibility Studies on On Halloysite Nanotubes in Novel Cell Separation Devices

(Nanowerk News) NaturalNano, Inc. Acting CEO and President James Wemett announced today that a series of feasibility studies have been initiated under the direction of Professor Michael King, Ph.D. of the Department of Biomedical Engineering at Cornell University in Ithaca New York and in co-operation with CellTraffix Inc. Dr King will be assessing whether NaturalNano’s proprietary Halloysite nanotubes enhance the adhesion of circulating cells to reactive surfaces, and thus hold promise for improving technologies of CellTraffix Inc. for the isolation of rare cell populations from blood or other samples, particularly adult stem cells and cancer cells in the blood.
Dr. King is a pioneer in the use of microtubes coated with “selectin” protein to which the targeted cells adhere. Improvement of the adhesion of targeted cells in the blood and bone marrow would significantly advance prospects of commercializing devices for research uses as well as diagnostic and therapeutic applications of this groundbreaking technology which would represent a significant advance over current cell collection methods.
“Our results obtained so far indicate that monolayer coatings of these interesting halloysite nanotubes result in significantly altered protein deposition and surface interactions with cells. We are now initiating tests of these coatings with clinical cell samples,” says King.
Mr. Wemett said “We are pleased with the results and excited to be working with such a prestigious University and the professional lab of Dr. King”
This work on Halloysite nanotubes by to be carried out by Dr. King is an opportunity to significantly advance our progress in developing a device that can be used commercially to isolate stem or certain cancer cells,” said Thomas Fitzgerald, CEO of CellTraffix, which is commercializing the research done by Dr. King and his team.
About NaturalNano, Inc.
NaturalNano, Inc. is a materials science company focused on developing and commercializing advanced nanocomposites. Based in Rochester, NY, the Company is focused on additive technologies and processes, including its proprietary Pleximer™ polymer additive, that add value to industrial polymers, plastics and composites, as well as consumer and industrial products. NaturalNano holds and licenses over 25 patents and applications, as well as proprietary know-how for extraction and separation processes, compositions, and derivatives of Halloysite and other nanotubes. Visit for more information.
About CellTraffix Inc.
CellTraffix employs its unique understanding of the mechanics of cellular flow and cell trafficking in the blood stream to develop a range of proprietary medical devices. These are based on the CellSelect technology ranging from simple, low cost research tools for the separation and collection of cells in blood, to sophisticated in vivo and ex vivo therapeutic delivery systems and diagnostics to address a number of unmet medical needs relating to cancer, adult stem cells and immune cells.
Source: NaturalNano (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: